Expert shares anticipated research directions for PSMA-PET in prostate cancer

In this video, Jitesh Dhingra, MD, FRCEM, discusses current and future research directions in the field of PSMA-PET imaging for prostate cancer. Dhingra is an attending nuclear medicine physician at Allegheny Health Network in Pittsburgh, Pennsylvania.

Transcription:

What are the current and future research directions in the field of PSMA-PET imaging for prostate cancer, and what advancements can we expect in the coming years?

The tracer that is probably going to be coming soon is called Posluma. Once we have Posluma, which is also a PSMA-based tracer, we'll have a better assessment of patients who will be benefiting from PSMA-based therapies like Lutetium-based theranostics. That's one big thing that I'm looking forward to. The other thing that I think is going to be really, really helpful is the utility of dosimetry. At this point of time, we are not doing dosimetry on any of our patients, but once we start using Posluma, we'll get a better assessment of what lesions and tumor sites are present in a patient, and we'll be able to use and translate that information toward dosimetry and directing our theranostic or PSMA-based therapies in a much more precise manner. That's another thing. The third thing I'm already currently working on clinical trials with these patients is that we are trying to use PSMA-based therapies in an adjuvant setting. So patients who have prostate cancer with a highly aggressive variant, we are using PSMA-based therapies in an adjuvant setting much earlier to even using chemotherapy at this point of time. That's another area that we are very excited about. There are many more things that I can keep talking about, but I would basically look at these 3 things as the major things to be coming up.

This transcript was AI generated and edited by human editors for clarity.